A kind of pharmaceutical composition of chronic sinusitis postnasal endoscopy
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for chronic sinusitis and composition, applied in the field of traditional Chinese medicine, can solve problems such as side effects, adhesions, and patient complications in the human body
Active Publication Date: 2015-09-30
黑龙江省普善医疗器械有限公司
View PDF1 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0003] Endoscopic sinus surgery is currently the most effective method for the treatment of chronic sinusitis and nasal polyps. However, due to the diversity of etiologies and the complexity of pathophysiological outcomes, after endoscopic sinus surgery, there are adverse factors in the operative cavity, such as Infection, granulation, vesicles, mucosal edema at the operation site, impaired mucociliary clearance system function, secretion retention, etc., affect the recovery of the wound and mucosa. For the recovery of the wound and mucosa, postoperative follow-up and comprehensive treatment are important. ring
At present, in clinical practice, normal saline, gentamicin injection and dexamethasone injection are often used to flush the surgical cavity after surgery, which has the advantages of short retention time in the nasal cavity, easy evaporation of the medicinal solution, dry nasal cavity and long-term use of hormones, gentamicin, etc. The application of antibiotics is easy to produce side effects on the human body and other disadvantages, and after use, there are still many patients with postoperative mucosal edema, vesicles, granulation, polyp regeneration, and nasal adhesions, which lead to surgical failure
After nasal endoscopic surgery, in addition to nasal cleaning and dressing changes, intranasal corticosteroids, antibiotics, and antihistamines are routinely used for treatment, but the price is relatively expensive, and long-term medication brings complications and side effects to patients
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
[0026] Weigh the above raw materials, add water and decoct three times, add twice the amount of water each time, decoct for one hour each time, filter, combine the filtrate, and make a decoction according to the conventional process.
[0029]Weigh the above raw materials according to the ratio, dry, crush, pass through an 80-mesh sieve, soak in 40kg of 50-degree rice wine for 2 months, filter to remove residue, take the supernatant, add the usual amount of penetrant and preservative, shake evenly and serve spray.
[0032] Weigh the above raw materials according to the ratio, add water to decoct twice, add 7 times the amount of water for the first time, decoct for 1.5 hours, add 8 times the amount of water for the second time, decoct for 1.5 hours, combine the decoction, filter, and filtrate Concentrate the extract to a relative density of 1.30 (measured at 70°C), add a conventional amount of sucrose powder, and mix well to make granules.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses a pharmaceutical composition for chronic nasosinusitis after endoscopic surgery. The pharmaceutical composition is prepared from following raw materials by weight: 12-28 parts of radix codonopsis, 12-28 parts of prepared rehmannia root, 10-20 parts of Chinese angelica, 10-20 parts of bighead atractylodes rhizome, 6-14 parts of white paeony root, 6-14 parts of pseudo-ginseng and 4-8 parts of licorice. The raw materials are active components. Lack of drugs after the endoscopic surgery for the chronic nasosinusitis at present is overcome. The pharmaceutical composition with good treating effects for the chronic nasosinusitis after the endoscopic surgery is provided.
Description
technical field [0001] The invention relates to the technical field of traditional Chinese medicine, in particular to a pharmaceutical composition for chronic sinusitis after endoscopic sinus surgery. Background technique [0002] Chronic sinusitis is a common clinical disease and frequently-occurring disease, mainly manifested as nasal congestion, runny nose, dizziness, headache, hyposmia, inattention, memory loss and other symptoms, seriously affecting the study and life of patients. The pathogenesis of chronic sinusitis is the result of multiple pathogenic factors, including local pathogenic bacterial infection, increased body allergy, microcirculation disorder, deformity of the mouth and nose complex, and low systemic immunity, etc., resulting in nasal mucosal edema, Thickening and polypoid changes, cystic changes, or fibrous tissue hyperplasia, vascular obstruction, glandular atrophy, and mucosal atrophy. Treatment of Western medicine is mainly symptomatic treatment su...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more